Real world studies in infrequently exacerbating patients with COPD

Brian Lipworth; Chris Kuo

doi:10.1016/j.chest.2019.04.094

Real world studies in infrequently exacerbating patients with COPD

Brian Lipworth (Lead / Corresponding author), Chris Kuo

Research output: Contribution to journal › Letter › peer-review

50 Downloads (Pure)

Abstract

The benefits of inhaled corticosteroids (ICS) as dual- or triple-combination therapy are more pronounced in patients with the frequent exacerbating eosinophilic (FEE) phenotype of COPD, corresponding to Global Initiative for Chronic Obstructive Lung Disease (GOLD) group D.1 In the June issue of CHEST, the real-life study by Suissa et al2 looks at a cohort of patients with COPD in whom 82% had zero or one prior exacerbation, corresponding to GOLD group B. In infrequently exacerbating patients one might expect there to be little impact conferred by using an ICS in combination with a long-acting β-agonist (LABA).

Original language	English
Pages (from-to)	415-416
Number of pages	2
Journal	Chest
Volume	156
Issue number	2
DOIs	https://doi.org/10.1016/j.chest.2019.04.094
Publication status	Published - Aug 2019

Keywords

COPD
Inhaled corticosteroids
Long acting bronchodilators

ASJC Scopus subject areas

Critical Care and Intensive Care Medicine
Cardiology and Cardiovascular Medicine
Pulmonary and Respiratory Medicine

Access to Document

10.1016/j.chest.2019.04.094

Author Accepted ManuscriptAccepted author manuscript, 117 KBLicence: CC BY-NC-ND

Cite this

@article{de8380d85ddd45159055b579a6c7afd5,

title = "Real world studies in infrequently exacerbating patients with COPD",

abstract = "The benefits of inhaled corticosteroids (ICS) as dual- or triple-combination therapy are more pronounced in patients with the frequent exacerbating eosinophilic (FEE) phenotype of COPD, corresponding to Global Initiative for Chronic Obstructive Lung Disease (GOLD) group D.1 In the June issue of CHEST, the real-life study by Suissa et al2 looks at a cohort of patients with COPD in whom 82% had zero or one prior exacerbation, corresponding to GOLD group B. In infrequently exacerbating patients one might expect there to be little impact conferred by using an ICS in combination with a long-acting β-agonist (LABA).",

keywords = "COPD, Inhaled corticosteroids, Long acting bronchodilators",

author = "Brian Lipworth and Chris Kuo",

year = "2019",

month = aug,

doi = "10.1016/j.chest.2019.04.094",

language = "English",

volume = "156",

pages = "415--416",

journal = "Chest",

issn = "0012-3692",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - Real world studies in infrequently exacerbating patients with COPD

AU - Lipworth, Brian

AU - Kuo, Chris

PY - 2019/8

Y1 - 2019/8

N2 - The benefits of inhaled corticosteroids (ICS) as dual- or triple-combination therapy are more pronounced in patients with the frequent exacerbating eosinophilic (FEE) phenotype of COPD, corresponding to Global Initiative for Chronic Obstructive Lung Disease (GOLD) group D.1 In the June issue of CHEST, the real-life study by Suissa et al2 looks at a cohort of patients with COPD in whom 82% had zero or one prior exacerbation, corresponding to GOLD group B. In infrequently exacerbating patients one might expect there to be little impact conferred by using an ICS in combination with a long-acting β-agonist (LABA).

AB - The benefits of inhaled corticosteroids (ICS) as dual- or triple-combination therapy are more pronounced in patients with the frequent exacerbating eosinophilic (FEE) phenotype of COPD, corresponding to Global Initiative for Chronic Obstructive Lung Disease (GOLD) group D.1 In the June issue of CHEST, the real-life study by Suissa et al2 looks at a cohort of patients with COPD in whom 82% had zero or one prior exacerbation, corresponding to GOLD group B. In infrequently exacerbating patients one might expect there to be little impact conferred by using an ICS in combination with a long-acting β-agonist (LABA).

KW - COPD

KW - Inhaled corticosteroids

KW - Long acting bronchodilators

UR - http://www.scopus.com/inward/record.url?scp=85069690041&partnerID=8YFLogxK

U2 - 10.1016/j.chest.2019.04.094

DO - 10.1016/j.chest.2019.04.094

M3 - Letter

C2 - 31395260

SN - 0012-3692

VL - 156

SP - 415

EP - 416

JO - Chest

JF - Chest

IS - 2

ER -

Real world studies in infrequently exacerbating patients with COPD

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this